# Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct06616987/  
OnCo record `nct06616987` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sacituzumab govitecan and pegfilgrastim in triple-negative breast cancer, run by Yeon Hee Park, now recruiting.

## Summary

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT06616987 by Yeon Hee Park, with a registry enrolment figure of 40 participants, started 2025-07-03 and due to reach its primary completion in 2027-06-30. Interventions recorded: Sacituzumab Govitecan with pegfilgrastim. Conditions listed: Breast Cancer Metastatic. Triple-negative eligibility wording from the registry: "Histologically confirmed TNBC per American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) criteria based on local testing on the most recent analyzed biopsy". Sites: South Korea. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06616987
- Phase: 2
- Setting: A Multicenter, Open-label, Single-arm, Clinical Trial to Evaluate the Preventive Effect of Pegylated G-CSF (PG) on Neutropenia in Patients With Metastatic Triple-negative Breast Cancer (mTNBC) Receiving Sacituzumab Govitecan (SG)
- Sponsor: Yeon Hee Park
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT06616987: https://clinicaltrials.gov/study/NCT06616987

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Pegfilgrastim](https://onco.cc/drugs/pegfilgrastim/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06616987.json